(Q44564339)

4 December 2017

Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study (English)

1 reference

4 December 2017

1 reference

G Blick

1

1 reference

4 December 2017

P Greiger-Zanlungo

2

1 reference

4 December 2017

S Gretz

3

1 reference

4 December 2017

J Han

4

1 reference

4 December 2017

D Dupree

5

1 reference

4 December 2017

T Garton

6

1 reference

4 December 2017

L H Yau

7

1 reference

4 December 2017

B C Wine

8

1 reference

4 December 2017

G E Pakes

9

1 reference

4 December 2017

Boosting Once-daily Lexiva Delivery with ritonavir 100 mg QD [BOLD100] Study Team

10

1 reference

4 December 2017

1 March 2012

1 reference

International Journal of STD & AIDS

4 December 2017

1 reference

4 December 2017

23

1 reference

4 December 2017

3

1 reference

4 December 2017

e18-22

1 reference

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

4 December 2017

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2009.009161

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2009.009161

Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2009.009161

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2009.009161

Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2009.009161

A review of low-dose ritonavir in protease inhibitor combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2009.009161

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2009.009161

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2009.009161

Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2009.009161

Tipranavir: a review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2009.009161

21 January 2018

Identifiers

DOI

10.1258/IJSA.2009.009161

1 reference

4 December 2017

1 reference